PDF(Pubmed)
Abstract：
Cancer is an important public health problem. Prostate cancer is one of the most common cancers among men. In Poland, the incidence of this type of cancer is constantly growing. Considering the appearance of a new coronavirus in December 2019 (SARS-CoV-2) and the fact that oncology patients, including those with prostate cancer, are particularly vulnerable to infection, it is recommended to get vaccinated against COVID-19. In our study, we determined the level and prevalence of antibodies against SARS-CoV-2 IgG in patients with prostate cancer compared to the control group and whether the patients\' ages affected the level of antibodies. PCa patients and controls were divided into two age groups: 50-59 years and 60-70 years. We also analyzed the level of antibodies in patients belonging to the relevant risk groups for prostate cancer (the European Society of Urology risk group classification of prostate cancer). For the study, we used the Microblot-Array COVID-19 IgG test to detect antibodies against the three main SARS-CoV-2 antigens: NCP, RBD, and S2. Our results showed that prostate cancer patients had significantly lower levels of anti-SARS-CoV-2 IgG antibodies compared to controls. In addition, age also affected the decrease in the number of IgG antibodies. The level of antibodies in the intermediate/high-risk group was lower compared to the low-risk group.
摘要：
癌症是一个重要的公共卫生问题。前列腺癌是男性中最常见的癌症之一。在波兰,这种癌症的发病率在不断增长。考虑到2019年12月新型冠状病毒（SARS-CoV-2）的出现以及肿瘤患者，包括前列腺癌患者，特别容易受到感染，建议接种COVID-19疫苗。在我们的研究中,我们确定了与对照组相比,前列腺癌患者的SARS-CoV-2IgG抗体水平和患病率,以及患者年龄是否影响抗体水平.PCa患者和对照组分为两个年龄组：50-59岁和60-70岁。我们还分析了前列腺癌相关风险组患者的抗体水平（欧洲泌尿外科学会前列腺癌风险组分类）。对于这项研究，我们使用Microblot-ArrayCOVID-19IgG测试来检测针对三种主要SARS-CoV-2抗原的抗体：NCP，RBD,和S2。我们的结果表明，与对照组相比，前列腺癌患者的抗SARS-CoV-2IgG抗体水平显着降低。此外,年龄也影响IgG抗体数量的减少。中/高风险组的抗体水平低于低风险组。
